Guidelines and reported practice for the treatment of hypertension and hypercholesterolaemia

Journal of Internal Medicine

Volumn 242, Issue 2, 1997, Pages 173-178

  Troein, Margareta ^a,c   Gardell, B ^a   Selander, S ^b   Rastam L ^a  

^a LUND UNIVERSITY   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hypercholesterolaemia; Hypertension; Practice guidelines

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ARTICLE; CLINICAL PRACTICE; DRUG CHOICE; GENERAL PRACTITIONER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0030856510     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.00182.x     Document Type: Article

References (30)

1. Harvald B. Making doctors change. J Intern Med 1996; 239: 191-3.
2. Grimshaw JM, Russell IT. Effects of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-22.
3. Eddy D. Practice policies: what are they? JAMA 1990; 263: 877-80.
4. Grol R. Development of guidelines for general practice. Br J Gen Pract 1993; 43: 146-51.
5. Strandberg K, Beermann B, Lönnerholm G. eds. Treatment of Mild Hypertension. Uppsala: National Board of Health and Welfare Drug Information Committee 1987.
6. Individualiserad hypertonibehandling [Individualised treatment of hypertension]. Information from the National Board of Health and Welfare Drug Information Committee 1990; 15: 109-64 (in Swedish).
7. Strandberg K, Beermann B, Lönnerholm G. eds. Treatment of Hyperlipidemia, Uppsala: National Board of Health and Welfare Drug Information Committee, 1989.
8. Troein M, Råstain L, Selander S. Dissemination and implementation of guidelines for lipid lowering. Fam Pract 1991; 8: 223-8.
9. Troein M, Arneson T, Pirie PL, Råstain L, Selander S, Luepker RV. Reported treatment of hypertension by family physicians in Sweden and Minnesota. J Intern Med 1995; 238: 215-21.
10. Troein M, Arneson T, Pirie PL, Rastam L, Selander S, Luepker RV. Reported treatment of hypercholesterolemia by family physicians in Sweden and Minnesota. Am J Prev Med 1995; 11: 324-8.
11. Kofron PM, Råstam L, Pirie PL, Holder W, Luepker RV. Physician practice for cardiovascular disease risk factor reduction in six upper Midwestern communities. J Fam Pract 1991; 32: 49-55.
12. Bostick RM, Luepker RV, Kofron PM, Pirie PL. Changes in physician practice for the prevention of cardiovascular disease. Arch Intern Med 1991; 151: 478-84.
13. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? N Engl J Med 1989; 321: 1306-11.
14. McBride P, Underbakke G. Cholesterol management - are guidelines effective? J Fam Pract 1991; 33: 237-9.
15. Muldoon MF, Manuck SB. Health through cholesterol reduction: are there unforeseen risks? Ann Behav Med 1992; 14: 101-8.
16. Lindberg G, Råstain L, Gullberg B, Eklund GA. Low serum cholesterol concentration and short term mortality from injuries in men and women. Br Med J 1992; 305: 277-9.
17. Jacobs DR Jr, Muldoon MF, Råstam L. Invited commentary: low blood cholesterol, nonillness mortality, and other nonatherosclerotic disease mortality; a search for causes and confounders. Am J Epidemiol 1995; 141: 518-22.
18. Dahlgren LO, Diwan VK, Tomson G, Wahlström R. On the variation among primary care physicians regarding hypercholesterolaemia: a phenomenographic analysis. Scan J Prim Health Care 1992; 10: 316-20.
19. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Br Med J 1993; 307: 1541-6.
20. National Board of Health and Welfare Drug Information Committee. Behandling av hyperlipidemi. Rekommendationer. [Treatment of hyperlipidemia. Recommendations]. Stockholm: National Board of Health and Welfare Drug Information Committee, 1995; 6: 178-87 (in Swedish).
21. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
23. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
24. Thomson R, Lavender M, Madhok R. How to ensure that guidelines are effective. Br Med 1995; 311: 237-42.
25. Thomas S. Standard setting In the Netherlands: Impact of the human factor on guideline development. Br J Gen Pract 1994; 44: 242-3.
26. Grot R, Thomas S, Roberts R. Development and implementation of guidelines for family practice: lessons from the Netherlands. J Fam Pract 1995; 40: 435-9.
27. Schucker R, Wittes JT, Santanello NC, Weber SJ, McGoldrick D, Donato K et al. Change in cholesterol awareness and action. Results from national physician and public surveys. Arch Intern Med 1991; 151: 666-73.
28. Diwan VK, Wahlström R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of 'group detailing' on the prescribing of lipid-lowering drugs: a randomised controlled that in Swedish primary care. J Clin Epidem: 1995; 48: 705-11.
29. Barton M, Schoenbaum S. Improving influenza vaccination performance in an HMO setting: the use of computer generated reminders and peer comparison feedback. Am J Publ Health 1990; 80: 534-6.
30. Eagle KA, Mulley AG, Skates SJ, Reder VA, Nicholson BW, Sexton JO et al. Length of stay in the intensive care unit. Effects of practice guidelines and feedback. JAMA 1990; 264: 992-7.